Exelixis slides as RBC trims target to $43 ahead of early-May earnings focus
Exelixis shares fell about 3% as investors reacted to a recent RBC Capital price-target cut to $43 from $46 while keeping a Sector Perform rating. The pullback also comes as the stock trades near the midpoint of Street targets ahead of expected early-May earnings, amplifying risk-off positioning.
1. What’s moving EXEL today
Exelixis (EXEL) is trading lower as the market digests a fresh sell-side reset: RBC Capital lowered its price target to $43 from $46 while reiterating a Sector Perform stance. With EXEL recently trading in the mid-$40s, the target cut reinforces a “range-bound” framing and can prompt short-term de-risking even without company-specific headlines.
2. Why the market cares right now
A price-target cut near current trading levels can matter disproportionately when a stock is between major catalysts. Exelixis’ next earnings update is widely expected in early May based on historical reporting patterns, and positioning tends to tighten as investors weigh near-term commercial trends for cabozantinib alongside longer-dated pipeline and regulatory milestones.
3. What to watch next
Near-term, investors will focus on any guidance reaffirmations or revisions, Cabometyx demand signals, and updates on zanzalintinib’s pivotal and regulatory timeline. Any new disclosure on trial timelines, regulatory feedback, or commercial execution could quickly dominate the tape and override today’s downgrade-driven pressure.